NASDAQ:GNCA
Delisted

Genocea Biosciences Stock Signals

etoro logo Buy GNCA
*Your capital is at risk
$0.0001
+0 (+0%)
At Close: Apr 19, 2023

Latest Data & Signals Issued

Below are some of the latest signals issued for Genocea Biosciences

General

Signal Type Signal Value Data
Score 0.000 60 days ( 0 %
Last Price $0.0001 0 %
Performance History
7 Days
$0.0001 $0.0001
0%
30 Days
$0.0001 $0.0001
0%
12 Mos
$0.461 $0.0001
-99.98%

3/18

Active Buy Signals

Specific Signals

Short Term
Net score: 15.54
Signal Type Signal Value Importance Data
High / Low N/A Very Low $0.0001 - $0.0001
Trend - 3 mos 0 % High Width: 0 %
Pred. range - 3 mos N/A - N/A Low -100.00 % - -100.00 %
Volume Direction Sell High Volume: 1 · Direction: 0
Pivot Short Buy Very Low Apr 18, 2023 - 2 days
RSI Short Pivot Signal Sell Very Low Nov 30, -0001 - N/A days
Short MA 3 mos Sell Low Nov 30, -0001 - N/A days
Long MA 3 mos Sell Medium Nov 30, -0001 - N/A days
Short/Long MA 3 mos Sell Medium Nov 30, -0001 - N/A days

Unlock Short Term Signals

Get access to powerful short-term trading signals and real-time market insights

Subscribe Now
Long Term
Net score: 22.83
Signal Type Signal Value Importance Data
Trend - 12 mos -40.21 % Very High Width: 180.03 %
Pred. range - 12 mos N/A - $0.148 High -100.00 % - 147,674.01 %
Short MA 12 mos Sell Very High Dec 20, 2022 - 82 days
Long MA 12 mos Sell Very High Nov 23, 2022 - 100 days
Short/Long MA 12 mos Sell Very High Nov 30, -0001 - N/A days
Pivot Long Buy Low Jan 06, 2023 - 71 days
RSI Long Pivot Signal Buy Low Jan 19, 2023 - 63 days
Bollinger Sell Medium Nov 30, -0001 - N/A days
MACD Neutral High No Dates Stored For This Signal
Click to get the best stock tips daily for free!
ABOUT GENOCEA BIOSCIENCES
Genocea Biosciences
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of so...
GOLDEN STAR
Ticker Change Signal Date
IDYA
$28.98
18.12% Jun 12
DHI
$146.71
6.39% Jun 10
E
ETD
$20.67
4.79% Jun 05
EAT
$140.46
16.94% Jun 05
TPR
$140.47
7.16% Jun 04

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE